Aerovate Therapeutics, Inc. (AVTE) Misses Q2 EPS by 6c

Aerovate Therapeutics, Inc. (NASDAQ: AVTE) reported Q2 EPS of ($0.76), $0.06 worse than the analyst estimate of ($0.70).

For earnings history and earnings-related data on Aerovate Therapeutics, Inc. (AVTE) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• Femcare acquires UK harm reduction firm Orion for £3.6M
• KeyBanc on National Fuel Gas (NFG): 'P&S Growth an Underappreciated Hedge to Weak Natural Gas Prices'